On October 27, 2026, Anthropic detailed its collaborations with six organizations using Claude and its scientific research environment for drug development. Generate Biomedicines produced genetic instructions approximately 70% shorter for a CAR-T therapy, while Divergence Labs generated about 35,000 antibody designs targeting food allergies. BigHat Biosciences reported more than tenfold tighter binding, and Enveda reported an 89% reduction in regulatory documentation time. Most of these projects remain preclinical, and Anthropic also disclosed internal programs through its acquisition of Mithril Medicine, a biotechnology company focused on rare childhood muscular dystrophies.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
